Aytu BioPharma's GAAP loss for fiscal year 2021 was $58.289 million, up 4.3 times from $13.621 million in the previous year. Revenue increased 2.4 times to $65.632 million from $27.632 million a year earlier.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept